Article detail · 2023
The level of dementia biomarkers in type 2 diabetes mellitus
Cukurova Medical Journal
- Year
- 2023
- ISSN
2602-3032- Type
- article
Data source split
- YÖKSİS YÖKSİS article record
- OpenAlex OpenAlex enrichment (abstract, citations, topics)
Abstract
English (OpenAlex)
Purpose: Like Alzheimer's disease, a disease of the aging world, and metastasis in cancer, it is very important to elucidate the etiology of Type 2 diabetes, which causes tissue and organ damage by systematically spreading throughout. In this study, we aimed to examine whether markers used as biomarkers in Alzheimer's pathogenesis are effective in the pathogenesis of diabetes. Materials and Methods: In our study, 30 type 2 diabetics, 30 type 2 diabetics individuals with the risk of dementia as a result of mini-mental test, and 28 healthy individuals aged 50-70 years were included, and brain-derived neurotrophic factor (BDNF), dual-specificity tyrosine-regulated kinase 1 (DYRK1A), Tau, fatty acid binding proteins 7 (FABP7) levels were measured from plasma samples. Results: There was a significant difference between the diabetes group with a high risk of dementia (MMSE < 24) and the other groups in Tau, and FABP7 levels, but no significant differences were found in BDNF and DYRK1A levels. Conclusion: These biomarkers might be used to diagnose Alzheimer's disease in patients with T2D and at risk of dementia before resorting to other more expensive and invasive diagnostic methods.
Topics
- Neurological Disease Mechanisms and Treatments
- Alzheimer's disease research and treatments
- Neurological Disorders and Treatments
Primary topic Neurological Disease Mechanisms and Treatments